Serum ferritin predicted prognosis in patients with locally advanced pancreatic cancer

Future Oncology

Volumn 11, Issue 21, 2015, Pages 2905-2910

  Wang, Si Liang ^a   Cao, Shuo ^a   Wu, Rong ^a   Chi, Feng ^a   Tang, Mei Yue ^a   Jin, Xue Ying ^a   Chen, Xiao Dong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

chemoradiotherapy; locally advanced pancreatic carcinoma; prognosis; serum ferritin

Indexed keywords

FERRITIN; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; AGED; BLOOD; CANCER STAGING; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; FERRITINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIOTHERAPY; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84946230534     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.186     Document Type: Article

References (19)

1. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014).
2. Saif MW, Ledbetter L, Kaley K et al. Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma. Oncol. Lett. 8(3), 1302-1306 (2014).
3. Chan K, Shah K, Lien K et al. A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer. PLoS ONE 9(10), e108749 (2014).
4. Sudo K, Yamaguchi T, Ishihara T et al. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 80(1), 119-125 (2011).
5. Marthey L, Sa-Cunha A, Blanc JF et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann. Surg. Oncol. 22(1), 295-301 (2015).
6. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J. Clin. Oncol. 31(1). 23-29 (2013).
7. Ji M, Li XD, Shi HB et al. Clinical significance of serum ferritin in elderly patients with primary lung carcinoma. Tumour Biol. 35(10), 10195-10199 (2014).
8. Facciorusso A, Del Prete V, Antonino M et al. Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. J. Gastroenterol. Hepatol. 29(11), 1905-1910 (2014).
9. Petekkaya I, Aksoy S, Roach EC et al. Impact of inflammatory markers on the prognosis of patients with operable breast cancer. J. BUON 19(3), 673-680 (2014).
10. Joosten E, Meeuwissen J, Vandewinckele H et al. Iron status and colorectal cancer in symptomatic elderly patients. Am. J. Med. 121(12), 1072-1077 (2008).
11. Boeck S, Wittwer C, Heinemann V et al. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br. J. Cancer 108(8), 1684-1694 (2013).
12. Rochefort MM, Ankeny JS, Kadera BE et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann. Surg. Oncol. 20(13), 4322-4329 (2013).
13. Alkhateeb A, Zubritsky L, Kinsman B et al. Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease. J. Gastrointest. Cancer 45(2),161-167 (2014).
14. Ruddell RG, Hoang-Le D, Barwood JM et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 49(3), 887-900 (2009).
15. Kalousová M, Krechler T, Jáchymová M et al. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol. 33(5), 1695-1700 (2012).
16. Ludwig H, Müldür E, Endler G et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann. Oncol. 24(7), 1886-1892 (2013).
17. Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk-a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidemiol. Biomarkers Prev. 23(1), 12-31 (2014).
18. Wang W, Knovich MA, Coffman LG et al. Serum ferritin: past, present and future. Biochim. Biophys. Acta 1800(8), 760-769 (2010).
19. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim. Biophys. Acta 1836(2), 245-254 (2013).